XEMBIFY plus usual care to prevent infections
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have one of these diagnoses: B-cell chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or B-cell non-Hodgkin lymphoma (NHL) at the required stage
- Have low IgG antibody levels (specific test rules apply for MM)
- Have had at least 1 severe infection in the past year or at least 3 infections in the past year
- Be well enough to join the study (about 1.5 years or more life expectancy, and no other major problems that could stop participation)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether people with certain blood cancers can safely stop their immune support medicine (immunoglobulin, also called Ig) or whether they should continue. It also tests antibiotic prevention strategies to reduce the risk of serious infections.
This study tests whether a weekly infusion of a blood product called IgPro20 can help prevent infections in people with multiple myeloma who are already being treated with a bispecific antibody. If you qualify, you will receive the study treatment and be monitored for safety and infection rates.
This study tests whether a new immune therapy called XEMBIFY works as well as a standard treatment (Gamunex-C) for CIDP, a condition where the immune system damages nerves and causes weakness. Both are given as infusions under the skin every three weeks.
This trial compares two treatments—antibiotics or immunoglobulin (a blood product with infection-fighting antibodies)—to see which better prevents infections in people with certain blood cancers like CLL, multiple myeloma, or non-Hodgkin's lymphoma.
This study looks at whether a different dose of IVIg (antibody treatment through the vein) or adding antibiotics can help prevent infections in people with low antibody levels. It's for patients already on steady IVIg who cannot safely stop it.
This trial tests whether it is safe to stop or extend immunoglobulin (Ig) therapy for people with low antibody levels, or if switching to preventive antibiotics works just as well to prevent infections.
Hear when a new Hypogammaglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.